# Evaluation Results

Run: 2026-04-30 02:31 UTC  
Model: `gemini-2.5-flash` | Judge: `gemini-2.5-flash`

| id | question (truncated) | papers | claims | citation_acc | recency_3yr | faithfulness | cost_usd | latency_s | error |
|----|----------------------|:------:|:------:|:------------:|:-----------:|:------------:|:--------:|:---------:|-------|
| q01 | What is the current evidence on GLP-1 agonists for non-… | 44 | 15 | 1.00 | 0.82 | 0.00 | $0.0039 | 878.1 |  |
| q02 | What does recent evidence say about SGLT2 inhibitors in… | 60 | 12 | 1.00 | 0.62 | 0.00 | $0.0027 | 120.8 |  |
| q03 | Is there evidence supporting low-dose aspirin for prima… | 55 | 11 | 1.00 | 0.35 | 0.00 | $0.0027 | 133.2 |  |
| q04 | What is the evidence base for continuous glucose monito… | 38 | 15 | 1.00 | 0.89 | 0.00 | $0.0031 | 551.8 |  |
| q05 | What are the current evidence-based recommendations for… | 61 | 14 | 1.00 | 0.66 | 0.00 | $0.0036 | 115.5 |  |

## Summary
- Questions run: 5 (5 succeeded, 0 failed)
- Avg faithfulness: 0.00
- Avg recency (3yr): 0.67
- Avg latency: 359.9s
- Total cost: $0.0160

---

## Literature Reviews

### [q01] What is the current evidence on GLP-1 agonists for non-diabetic weight management?

{
  "review": "## Current Evidence on GLP-1 Agonists for Non-Diabetic Weight Management\n\n### Summary\nGLP-1 agonists, particularly semaglutide and orforglipron, demonstrate significant efficacy in weight reduction for non-diabetic adults with overweight or obesity, often achieving placebo-adjusted weight reductions of 10% or more [Shenyue et al., 2026; Ying et al., 2026]. While generally effective and superior to lifestyle counselling alone, their use is associated with an overall increase in heart rate and requires careful patient selection and monitoring due to observed elevated serious adverse events [B et al., 2026; Shenyue et al., 2026; Yiwen et al., 2026].\n\n### Evidence Overview\nThe current evidence on GLP-1 agonists for non-diabetic weight management primarily consists of systematic reviews and meta-analyses, including network meta-analyses of randomized controlled trials (RCTs), alongside one multi-site, retrospective observational study. Specifically, one network meta-analysis included 19 RCTs involving 13,117 participants [Ying et al., 2026], another systematic review and meta-analysis encompassed twelve RCTs [Yiwen et al., 2026], and a separate meta-analysis included seven RCTs with 5,411 non-diabetic adults [Shenyue et al., 2026]. The observational study utilized electronic health records from 3,927 adult participants, comparing semaglutide to lifestyle counselling [B et al., 2026]. This body of evidence provides a strong basis for evaluating efficacy and some safety aspects.\n\n### Key Findings\n*   Semaglutide significantly reduced absolute weight by -12.24 kg (95% CI -13.25 to -11.22) and percentage weight by -12.15% (95% CI -13.63 to -10.67) compared to placebo in non-diabetic adults with overweight or obesity [Shenyue et al., 2026].\n*   Semaglutide 7.2 mg achieved the highest cardiometabolic efficacy index (CEI) of 0.86, followed by orforglipron 36 mg (0.68) and semaglutide 2.4 mg (0.66), with these three agents demonstrating placebo-adjusted weight reductions of ≥10% [Ying et al., 2026].\n*   Semaglutide therapy is more effective than lifestyle counselling alone in achieving at least 10% weight loss in non-diabetic populations, with a hazard ratio of 1.63 (95% CI: 1.32, 2.01) [B et al., 2026].\n*   GLP-1 receptor mono-agonists' cardiometabolic efficacy index rankings were generally consistent across subgroups, including those without type 2 diabetes [Ying et al., 2026].\n*   GLP-1 receptor agonists (GLP-1RAs) were associated with an overall increase in heart rate compared to placebo (MD = 3.47 bpm; 95% CI 2.65, 4.29) in non-diabetic individuals with overweight or obesity [Yiwen et al., 2026].\n*   Among the studied GLP-1RAs, orforglipron 36 mg showed the most pronounced heart rate increase (MD = 9.29 bpm; 95% CI 4.45, 13.86), while tirzepatide 5 mg was associated with the least increase (MD = 0.52 bpm; 95% CI -2.71, 3.78) in non-diabetic individuals [Yiwen et al., 2026].\n*   While semaglutide's safety profile is generally acceptable, elevated serious adverse events were observed, necessitating careful patient selection and monitoring in non-diabetic adults with overweight or obesity [Shenyue et al., 2026].\n*   Optimal weight management outcomes with both oral and subcutaneous semaglutide occur when combined with lifestyle interventions at doses ≥2.4 mg weekly [Shenyue et al., 2026].\n\n### Limitations and Gaps\nWhile multiple meta-analyses of randomized controlled trials provide robust efficacy data, detailed long-term safety profiles, beyond heart rate increases, across all GLP-1RAs for non-diabetic individuals are not comprehensively described in the provided evidence. Specific details regarding the nature of "elevated serious adverse events" requiring careful monitoring are not elaborated [Shenyue et al., 2026]. One review noted no specific safety signals or study limitations were reported in its abstract, beyond domain-specific differences across agents, suggesting potential limitations in the granularity of reported safety data [Ying et al., 2026]. Furthermore, the observational study comparing semaglutide to lifestyle counselling, while informative, inherently carries limitations common to retrospective designs using electronic health records, which may not fully account for all confounding factors [B et al., 2026].\n\n### Clinical Implications\nGLP-1 agonists, particularly semaglutide, appear to be highly effective for weight management in non-diabetic individuals with overweight or obesity, offering superior weight loss compared to lifestyle counselling alone when combined with it [B et al., 2026; Shenyue et al., 2026]. Clinicians should consider these agents for appropriate patients, while exercising careful patient selection and monitoring due to potential side effects like increased heart rate and other serious adverse events [Shenyue et al., 2026; Yiwen et al., 2026].",
  "references": [
    "[Ying et al., 2026] Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41992023/",
    "[B et al., 2026] Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41830068/",
    "[Yiwen et al., 2026] Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41582189/",
    "[Shenyue et al., 2026] Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41580006/"
  ]
}

### [q02] What does recent evidence say about SGLT2 inhibitors in heart failure with preserved ejection fraction?

## Summary
Recent evidence indicates that SGLT2 inhibitors are an effective treatment for heart failure with preserved ejection fraction (HFpEF). A systematic review and meta-analysis of randomized controlled trials demonstrate that these inhibitors significantly reduce the risk of heart failure hospitalizations and all-cause mortality, with a safety profile comparable to placebo. [Peijian et al., 2026]

## Evidence Overview
The primary clinical evidence comes from a systematic review and meta-analysis which included six international multicenter randomized controlled trials (RCTs), enrolling a total of 16,543 participants with HFpEF. [Peijian et al., 2026] This robust body of evidence underpins the observed clinical benefits. Additionally, an analysis of 12 authoritative SGLT2 inhibitor guidelines using a neuro-symbolic framework provides insight into the structural complexities and potential conflicts within clinical recommendations, particularly concerning multimorbidity. [Xie et al., 2026]

## Key Findings
*   Treatment with SGLT-2 inhibitors significantly reduced the risk of heart failure hospitalizations compared to placebo (P<0.05) in patients with HFpEF. [Peijian et al., 2026]
*   A significant reduction in all-cause mortality was observed in the SGLT-2 inhibitor group. [Peijian et al., 2026]
*   Rates of adverse events were similar between the SGLT-2 inhibitor and placebo arms. [Peijian et al., 2026]
*   An analysis of SGLT2 inhibitor guidelines found that 90.6% of identified conflicts were 'Local Conflicts,' which are decision conflicts arising from the intersection of comorbidities and represent a structural complexity not addressed by single-disease guidelines. [Xie et al., 2026]

## Limitations and Gaps
The provided evidence strongly supports the clinical efficacy and safety of SGLT2 inhibitors in HFpEF based on a meta-analysis of RCTs. However, the evidence also points to challenges in the practical application of these treatments due to complexities in clinical guidelines. Specifically, a significant proportion of identified conflicts (90.6%) within SGLT2 inhibitor guidelines stem from 'Local Conflicts' related to patient comorbidities, suggesting that current single-disease guidelines may not adequately address the nuances of multimorbidity in real-world clinical settings. [Xie et al., 2026] The current evidence does not elaborate on specific differential outcomes between various SGLT2 inhibitors or their effects across different HFpEF patient subgroups.

## Clinical Implications
SGLT2 inhibitors are a valuable therapeutic class for patients with HFpEF, demonstrating clear benefits in reducing heart failure hospitalizations and all-cause mortality, accompanied by a favorable safety profile. [Peijian et al., 2026] Clinicians should consider these agents as a standard part of HFpEF management, while also being mindful of the complexities introduced by patient comorbidities, which may not be fully resolved by current clinical guidelines. [Xie et al., 2026]

**References**

- [Peijian et al., 2026] Impact of SGLT-2 inhibitors on long-term prognosis in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/42007145/
- [Xie et al., 2026] Neuro-Symbolic Resolution of Recommendation Conflicts in Multimorbidity Clinical Guidelines. Source: arxiv. https://arxiv.org/abs/2604.17340/

### [q03] Is there evidence supporting low-dose aspirin for primary prevention of cardiovascular disease post-2018?

### 1. Summary
The provided evidence, consisting of specific claims from a limited set of papers, does not contain information directly supporting or refuting the use of low-dose aspirin for the primary prevention of cardiovascular disease post-2018. The available claims focus on machine learning models for diabetes risk stratification and cardiovascular disease risk prediction in diabetic patients, as well as prompt compression techniques for AI systems.

### 2. Evidence Overview
The provided evidence comprises specific claims from three research papers. Two papers detail the development and evaluation of machine learning and deep learning models for health risk prediction [Parvez et al., 2025; Chowdhury et al., 2025]. Specifically, one addresses diabetes risk stratification using hybrid machine learning models [Parvez et al., 2025], and the other focuses on cardiovascular disease risk prediction among diabetic patients using various machine learning and deep learning techniques [Chowdhury et al., 2025]. The third paper investigates prompt compression in the context of multi-agent task orchestration [Johnson et al., 2026]. None of these claims pertain to the efficacy or safety of low-dose aspirin for cardiovascular primary prevention.

### 3. Key Findings
*   The XGBoost + Random Forest (XGB-RF) model achieved high performance (AUROC of ~0.995, AUPRC of ~0.998) for diabetes risk stratification on a primary dataset, surpassing the SVM-LR model [Parvez et al., 2025].
*   External validation on the PIMA cohort showed strong generalizability for the XGB-RF model (AUROC ~0.990, AUPRC ~0.959) in diabetes risk stratification, with an accuracy of 0.960 at a 0.5 threshold [Parvez et al., 2025].
*   Future work for gradient-boosting-based hybridization in diabetes risk stratification should include prospective, multi-site validation with deployment-time threshold selection [Parvez et al., 2025].
*   XGBoost and LSTM models demonstrated the highest accuracy (0.9050) for cardiovascular disease risk prediction among diabetic patients using the BRFSS dataset [Chowdhury et al., 2025].
*   Some machine learning and deep learning models achieved perfect recall (1.00) in predicting cardiovascular disease risk for diabetic patients [Chowdhury et al., 2025].
*   Moderate prompt compression (r=0.5) in AI systems reduced the mean total inference cost by 27.9% compared to an uncompressed control [Johnson et al., 2026].
*   Recency-weighted compression achieved 23.5% savings and, along with moderate compression, occupied the empirical cost-similarity Pareto frontier in prompt compression [Johnson et al., 2026].

### 4. Limitations and Gaps
A significant limitation is the complete absence of specific claims or findings within the provided evidence directly addressing low-dose aspirin for the primary prevention of cardiovascular disease. While the prompt listed several paper titles related to this topic published post-2018, no specific data, results, or conclusions from these studies were provided in the form of claims. Consequently, an assessment of the evidence supporting low-dose aspirin for primary prevention of cardiovascular disease cannot be made based on the supplied claims.

### 5. Clinical Implications
Based solely on the provided claims, no clinical implications regarding the use of low-dose aspirin for the primary prevention of cardiovascular disease can be derived. The available evidence primarily offers insights into advanced computational methods for risk stratification and prediction in diabetes and cardiovascular disease, which could inform targeted prevention strategies, but does not provide direct guidance on aspirin use.

**References**

- [Parvez et al., 2025] Generalizable Diabetes Risk Stratification via Hybrid Machine Learning Models. Source: arxiv. https://arxiv.org/abs/2509.20565
- [Johnson et al., 2026] Prompt Compression in Production Task Orchestration: A Pre-Registered Randomized Trial. Source: arxiv. https://arxiv.org/abs/2603.23525
- [Chowdhury et al., 2025] Risk Prediction of Cardiovascular Disease for Diabetic Patients with Machine Learning and Deep Learning Techniques. Source: arxiv. https://arxiv.org/abs/2511.04971

### [q04] What is the evidence base for continuous glucose monitoring in non-insulin-dependent type 2 diabetes?

### Summary
Evidence for continuous glucose monitoring (CGM) in non-insulin-dependent type 2 diabetes is limited but suggests potential for glycemic control. A small retrospective study indicated promising HbA1c reductions in this patient group, while a broader systematic review on T2DM generally associated CGM with HbA1c improvements. However, the overall impact on quality of life remains inconclusive, and robust research specifically for non-insulin-dependent individuals is needed.

### Evidence Overview
The evidence base for CGM in non-insulin-dependent type 2 diabetes primarily consists of a small retrospective chart review and findings from a systematic review focused on general adult T2DM patients. The retrospective study included 10 non-insulin-treated adults with an initial HbA1c >7% [Karimi et al., 2026]. The systematic review synthesized findings from five studies comparing CGM (flash or real-time) to self-blood glucose monitoring (SMBG) in adult T2DM patients, with included studies having moderate methodological quality (JADAD scores 2-3) [Dwiastuti et al., 2026].

### Key Findings
*   In a small retrospective study of 10 non-insulin-treated adults with type 2 diabetes, 8 of 9 patients achieved HbA1c reductions of ≥0.3% after 6 months of initial CGM use [Karimi et al., 2026].
*   This study observed early improvements in HbA1c, but sustained glycemic outcomes varied, underscoring that consistent CGM wear and adherence to follow-up are critical [Karimi et al., 2026].
*   A systematic review of adult T2DM patients found that CGM was consistently associated with greater HbA1c reduction than conventional SMBG, with two studies reporting statistically significant improvements [Dwiastuti et al., 2026].
*   Most studies included in the systematic review showed no significant difference in quality of life (QoL) between CGM and SMBG groups in adult T2DM patients, although one study did report a psychological benefit [Dwiastuti et al., 2026].
*   The overall impact of CGM on Quality of Life in T2DM patients remains inconclusive, with further long-term studies using diabetes-specific QoL tools needed [Dwiastuti et al., 2026].

### Limitations and Gaps
A significant limitation is the paucity of direct evidence specifically for non-insulin-dependent type 2 diabetes. Much of the robust evidence for CGM in T2DM, including large meta-analyses, focuses exclusively on patients on insulin therapy [Jingjing et al., 2026; Zhu et al., 2026]. The direct study for non-insulin-treated patients was a small retrospective chart review with a limited sample size (N=10), thereby limiting generalizability [Karimi et al., 2026]. The systematic review on T2DM broadly did not distinguish between insulin-dependent and non-insulin-dependent patients [Dwiastuti et al., 2026] and was based on a limited number of studies with moderate methodological quality. There is no specific evidence provided on time in range (TIR), time above range (TAR), or time below range (TBR) for non-insulin-dependent T2DM patients within the provided claims. The overall impact on quality of life remains inconclusive, indicating a need for more long-term studies using diabetes-specific QoL tools [Dwiastuti et al., 2026].

### Clinical Implications
While CGM shows potential for improving HbA1c in some non-insulin-treated T2DM patients, clinicians should consider the limited and preliminary nature of the current direct evidence. The importance of consistent CGM use and adherence to follow-up for sustained glycemic benefits should be emphasized. The evidence does not yet clearly support a significant, consistent improvement in quality of life for this patient group, suggesting that patient selection and further research are warranted.

**References**

- [Jingjing et al., 2026] Efficacy of continuous glucose monitoring in comparison to self-blood glucose monitoring in patients with type 2 diabetes mellitus under insulin treatment: a systematic review and meta-analysis.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41942969/
- [Zhu et al., 2026] Efficacy of continuous glucose monitoring in comparison to self-blood glucose monitoring in patients with type 2 diabetes mellitus under insulin treatment: a systematic review and meta-analysis. Source: semantic_scholar. https://www.semanticscholar.org/paper/b06b5603b5603dba98d718ece5b42c4bbf259b81
- [Karimi et al., 2026] Continuous glucose monitoring for glycemic control in non-insulin-treated patients with type 2 diabetes.. Source: semantic_scholar. https://www.semanticscholar.org/paper/74f79bcb35a3ff969f6fafeeb41f55077af76db8
- [Dwiastuti et al., 2026] Systematic Review of Continuous Glucose Monitoring and Its Effect on Quality of Life in Type 2 Diabetes Mellitus. Source: semantic_scholar. https://www.semanticscholar.org/paper/9acab3ce04a1ccce998c391d16b76d5c63f5508f

### [q05] What are the current evidence-based recommendations for duration of dual antiplatelet therapy after PCI?

### Summary
Current evidence suggests that shorter durations of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy may be beneficial after percutaneous coronary intervention (PCI), particularly for patients with acute coronary syndromes (ACS) or those at high bleeding risk (HBR). This strategy appears to reduce net adverse clinical events (NACE) and major adverse cardiovascular events (MACE) without increasing major bleeding risk in certain contexts, compared to standard DAPT durations [Muhammad et al., 2026; A et al., 2026; Pankaj et al., 2026].

### Evidence Overview
The evidence base includes a systematic review and meta-analysis of 10 randomized controlled trials (RCTs) involving 35,277 patients [Muhammad et al., 2026], an updated meta-analysis of 10 studies (RCTs and observational studies) comprising 162,829 patients [A et al., 2026], a retrospective observational study of 150 high bleeding risk (HBR) patients [Pankaj et al., 2026], and a narrative review synthesizing current pharmacodynamic and clinical outcomes evidence [Claudio et al., 2026]. The quality of evidence varies, with meta-analyses offering strong synthesis, but some primary data limitations noted.

### Key Findings
*   Short-term DAPT (≤3 months) followed by P2Y12 inhibitor monotherapy significantly reduced Net Adverse Clinical Events (NACE) (RR = 0.80, 95% CI 0.71-0.90; p = 0.0002) compared with standard-duration DAPT (≥6-12 months) in patients who underwent PCI for acute coronary syndromes [Muhammad et al., 2026].
*   Clopidogrel monotherapy, following standard DAPT after PCI, was significantly associated with a lower risk of major adverse cardiovascular events (MACE) (HR: 0.72, 95% CI: 0.66–0.79) compared to aspirin monotherapy [A et al., 2026].
*   Clopidogrel monotherapy was also associated with a lower risk of net adverse clinical events (NACE) (RR: 0.86, 95% CI: 0.73–0.99) compared to aspirin, with no observed difference in all-cause mortality, myocardial infarction, revascularization, stroke, or all bleeding. There was no significant difference in major bleeding risk (RR: 0.85, 95% CI: 0.60–1.21) [A et al., 2026].
*   For high bleeding risk (HBR) patients receiving Resolute Onyx stents, a strategy of 3-month DAPT followed by ticagrelor monotherapy resulted in low rates of definite/probable stent thrombosis (0.3%), target lesion failure (3.0%), stroke (0.6%), and importantly, no BARC 3-5 bleeding events at one year. The primary composite endpoint of cardiac death or MI was 5.7% from three months to one year [Pankaj et al., 2026].
*   Shortening DAPT in favor of single antiplatelet therapy (SAPT) in patients with coronary artery disease (CAD) undergoing PCI can optimize overall clinical benefit by preventing bleeding without a significant trade-off in ischemic events [Claudio et al., 2026].
*   There is an emphasis on a tailored antiplatelet treatment approach, requiring accurate evaluation of individual patient ischemic and bleeding risk profiles to guide regimen selection and duration [Claudio et al., 2026].

### Limitations and Gaps
The meta-analysis by Muhammad et al. [2026] had a truncated abstract, precluding the reporting of specific safety signals such as BARC 3 or 5 bleeding, as well as outcomes for MACE, all-cause and cardiovascular mortality, myocardial infarction, stroke, and stent thrombosis. The study by Pankaj et al. [2026] was a retrospective observational study on a small South Asian cohort of 150 HBR patients, and its findings require confirmation in larger, prospective studies. While evidence points to a general trend, detailed recommendations for all specific patient subgroups or across different P2Y12 inhibitors are not fully elaborated within the provided claims.

### Clinical Implications
These findings suggest a shift towards personalized and shorter DAPT durations followed by P2Y12 inhibitor monotherapy after PCI, particularly in patients with ACS and those at high bleeding risk, to reduce NACE and MACE. Clinicians should consider individual patient ischemic and bleeding risk profiles to tailor antiplatelet treatment regimens and duration, favoring P2Y12 inhibitor monotherapy over aspirin monotherapy where appropriate [A et al., 2026; Claudio et al., 2026].

**References**

- [Muhammad et al., 2026] Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Systematic Review and Meta-Analysis.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41671172/
- [A et al., 2026] Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: an updated meta-analysis of 162,829 patients.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41649579/
- [Pankaj et al., 2026] Short dual antiplatelet therapy after PCI with Resolute Onyx drug-eluting stents in high bleeding risk patients: One-year outcomes from a South Asian cohort.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41561403/
- [Claudio et al., 2026] The pharmacology and clinical evidence for the use of dual versus single antiplatelet therapy.. Source: pubmed. https://pubmed.ncbi.nlm.nih.gov/41493145/
